Claims

1. Use of a compound of formula I,



I

wherein
ring A is a benzene ring, wherein the benzene ring is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, alkyl, C(O)-NH, CN and -OCH_3;

Y is chosen from the series consisting of N(R^{10}), S, O, C(R^{12})=C(R^{13}), N=C(R^{14}) and C(R^{15})=N;

Z is chosen from the series consisting of N and C(R^{16});

R^{11}, R^{30}, R^{33} and R^{35} are, independently of each other groupR^{11}, R^{30}, R^{33} and R^{35}, chosen from the series consisting of (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl and (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl- which are all optionally substituted by one or more identical or different substituents R^{70};

R^3 and R^5 are independently of each other chosen from the series consisting of hydrogen, (C_1-C_4)-alkyl, phenyl-(C_1-C_4)-alkyl, phenyl and hydroxy;

R^4 and R^6 are independently of each other chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

R^{10} is chosen from the series consisting of hydrogen and R^{11};

R^{12}, R^{13}, R^{14}, R^{15} and R^{16} are independently of each other chosen from the series consisting of hydrogen, (C_1-C_4)-alkyl, HO-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_1-C_4)-alkyl-$S(O)_m$-, H_2N-, (C_1-C_4)-alkyl-NH-, (C_1-C_4)-alkyl-N((C_1-C_4)-alkyl), (C_1-C_4)-alkyl-C(O)-, NC- and O_2N-;

R^{20} is chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;
one of the groups R^{21} and R^{22} is a group of the formula II

R^{24}-R^{23}- II

and the other of the groups R^{21} and R^{22} is chosen from the series consisting of hydrogen, halogen, R^{30}, HO-, R^{30}-O-, R^{30}-C(O)-O-, R^{30}-$S(O)_2$-O-, R^{30}-$S(O)_m$-, H_2N-, R^{30}-NH-, R^{30}-N(R^{30})-, R^{30}-C(O)-NH-, R^{30}-C(O)-N(R^{71})-, R^{30}-$S(O)_2$-NH-, R^{30}-$S(O)_2$-N(R^{71})-, R^{30}-C(O)-, HO-C(O)-, R^{30}-O-C(O)-, H_2N-C(O)-, R^{30}-NH-C(O)-, R^{30}-N(R^{30})-C(O)-, H_2N-$S(O)_2$-, R^{30}-NH-$S(O)_2$-, R^{30}-N(R^{30})-$S(O)_2$-, NC-, O_2N- and Het^1;

R^{23} is a direct bond or a chain consisting of 1 to 5 chain members of which 0, 1 or 2 chain members are identical or different hetero chain members chosen from the series consisting of N(R^{25}), O, S, S(O) and $S(O)_2$, but two hetero chain members can be present in adjacent positions only if one of them is chosen from the series consisting of S(O) and $S(O)_2$ and the other is chosen from the series consisting of N(R^{25}), O and S, and the other chain members are identical or different groups C(R^{26})(R^{26}), wherein two adjacent groups C(R^{26})(R^{26}) can be connected to each other by a double bond or a triple bond;

R^{24} is a 3-membered to 7-membered monocyclic ring or a 7-membered to 10-membered bicyclic ring, which rings are saturated or unsaturated and contain 0, 1 or 2 identical or different hetero ring members chosen from the series consisting of N, N(R^{32}), O, S, S(O) and $S(O)_2$, and which rings are optionally substituted on ring carbon atoms by one or more identical or different substituents chosen from the series consisting of halogen, R^{33}, HO-, R^{33}-O-, R^{33}-$S(O)_m$-, H_2N-, R^{33}-NH-, R^{33}-N(R^{33})-, R^{33}-C(O)-NH-, R^{33}-C(O)-N(R^{71})-, R^{33}-$S(O)_2$-NH-, R^{33}-$S(O)_2$-N(R^{71})-, H_2N-$S(O)_2$-NH-, R^{33}-NH-$S(O)_2$-NH-, R^{33}-N(R^{33})-$S(O)_2$-NH-, H_2N-$S(O)_2$-N(R^{71})-, R^{33}-NH-$S(O)_2$-N(R^{71})-, R^{33}-N(R^{33})-$S(O)_2$-N(R^{71})-, HO-C(O)-, R^{33}-O-C(O)-, H_2N-C(O)-, R^{33}-NH-C(O)-, R^{33}-N(R^{33})-C(O)-, NC-, oxo, phenyl and Het,

provided that the total number of C, N, O and S atoms which is present in the two groups R^{23} and R^{24}, is at least 5;

R^{25} is chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

R^{26}, independently of each other group R^{26}, is chosen from the series consisting of hydrogen, fluorine, (C_1-C_4)-alkyl and HO-, or two groups R^{26} bonded to the same carbon atom together are oxo, or two of the groups R^{26} or one group R^{25} and one group R^{26}, together with the comprised chain members, form a 3-membered to 7-membered monocyclic ring which is saturated and contains 0, 1 or 2 identical or different hetero ring members chosen from the series consisting of N, N(R^{34}), O, S, S(O) and $S(O)_2$, which ring is optionally substituted on ring carbon atoms by one more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;
R^{32} is chosen from the series consisting of hydrogen, R^{35}, R^{35}-C(O)-, R^{35}-O-C(O)- and phenyl;

R^{34} is chosen from the series consisting of hydrogen, R^{35}, R^{35}-$S(O)_2$-, R^{35}-C(O)-, R^{35}-O-C(O)-, phenyl and Het;

R^{50} is chosen from the series consisting of -OH, -NH_2 and -OCH_3;

R^{60}, independently of each other group R^{60}, is chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

R^{70} is chosen from the series consisting of HO-, R^{71}-O-, R^{71}-C(O)-O-, R^{71}-$S(O)_m$-, H_2N-, R^{71}-NH-, R^{71}-N(R^{71})-, R^{71}-C(O)-NH-, R^{71}-C(O)-N(R^{71})-, R^{71}-$S(O)_2$-NH-, R^{71}-$S(O)_2$-N(R^{71})-, HO-C(O)-, R^{71}-O-C(O)-, H_2N-C(O)-, R^{71}-NH-C(O)-, R^{71}-N(R^{17})-C(O)-, H_2N-$S(O)_2$-, R^{71}-NH-$S(O)_2$-, R^{71}-N(R^{71})-$S(O)_2$-, NC-, oxo, phenyl and Het^2;

R^{71}, independently of each other group R^{71}, is chosen from (C_1-C_4)-alkyl, (C_3-C_4)-cycloalkyl and (C_3-C_4)-cycloalkyl-(C_1-C_2)-alkyl-;

Het, independently of each other group Het, is a monocyclic 4-membered to 7-membered heterocyclic ring which comprises 1, 2 or 3 identical or different hetero ring members chosen from the series consisting of N, N(R^{60}), O, S, S(O) and $S(O)_2$, which ring is saturated or unsaturated and is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl and R^{70};

Het^1 is a monocyclic 4-membered to 7-membered heterocyclic ring which comprises 1 or 2 identical or different hetero ring members chosen from the series consisting of N, $N(R^{60})$, O, S, S(O) and $S(O)_2$, which ring is saturated and is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

Het^2 is a monocyclic 5-membered or 6-membered heterocyclic ring which comprises 1, 2 or 3 identical or different hetero ring members chosen from the series consisting of N, $N(R^{60})$, O and S, which ring is aromatic and is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_1$-$C_4)$-alkyl-O- and NC-;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

phenyl, independently of each other group phenyl, is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_1$-$C_4)$-alkyl-O- and NC-, unless specified otherwise;

cycloalkyl, independently of each other group cycloalkyl, and independently of any other substituents on cycloalkyl, is optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl; and

alkyl, alkenyl and alkynyl, independently of each other group alkyl, alkenyl and alkynyl, and independently of any other substituents on alkyl, alkenyl and alkynyl, is optionally substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

provided that the compound of the formula I is not 2-[(6,2′,4′-trichlorobiphenyl-3-carbonyl)amino]indane-2-carboxylic acid, 2-[6-chloro-[1,1′,4′,1″]terphenyl-3-carbonyl)amino]indane-2-carboxylic acid, 2-(4-chloro-3-phenylethynyl-benzoylamino)-indane-2-carboxylic acid, 5-(4-chloro-phenyl)-2-[4-(2-methyl-1H-benzoimidazol-1-ylmethyl)-benzoylamino]-indane-2-carboxylic acid or 5-(4-chloro-

phenyl)-2-[4-(2-methyl-1H-benzoimidazol-1-ylmethyl)-benzoylamino]-indane-2-carboxylic acid ethyl ester,

in the manufacture of a medicament for the treatment of a fibrotic disease in a patient.

2. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:

R^3 and R^5 are independently of each other chosen from the series consisting of hydrogen, (C_1-C_4)-alkyl, phenyl-(C_1-C_4)-alkyl- and phenyl.

3. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:
Y is chosen from the series consisting of S, C(R^{12})=C(R^{13}), and C(R^{15})=N; and
Z is C(R^{16}).

4. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:

ring A is a benzene ring, which is optionally substituted by one or two identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl and (C_1-C_4)-alkyl-O-;

Y is chosen from the series consisting of S, C(R^{12})=C(R^{13}) and C(R^{15})=N;

Z is C(R^{16});

R^3 and R^5 are independently of each other chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

R^4 and R^6 are hydrogen;

R^{12}, R^{13}, R^{15} and R^{16} are independently of each other chosen from the series consisting of hydrogen, halogen (C_1-C_4)-alkyl, (C_1-C_4)-alkyl-O- and NC-; and

R^{20} is hydrogen.

5. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:

   R^{21} is chosen from the series consisting of hydrogen, halogen, (C_1-C_4)-alkyl, HO-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_1-C_4)-alkyl-S(O)$_m$-, H_2N-, (C_1-C_4)-alkyl-NH-, di((C_1-C_4)-alkyl)N-, (C_1-C_4)-alkyl-C(O)- and NC-;

   R^{22} is a group of the formula II;

   R^{24}-R^{23}- II

   R^{23} is a direct bond or a chain consisting of 2, 3 or 4 chain members of which 0 or 1 chain members are hetero chain members chosen from the series consisting of N(R^{25}), O, S, S(O) and $S(O)_2$, and the other chain members are identical or different groups C(R^{26})(R^{26}), wherein two adjacent groups C(R^{26})(R^{26}) can be connected to each other by a double bond or a triple bond.

6. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:

   ring A is a benzene ring, which is optionally substituted by one or two identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl and (C_1-C_4)-alkyl-O-;

   Y is chosen from the series consisting of S, C(R^{12})=C(R^{13}) and C(R^{15})=N;

   Z is C(R^{16});

   R^3 and R^5 are independently of each other chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

   R^4 and R^6 are hydrogen;

   R^{12}, R^{13}, R^{15} and R^{16} are independently of each other chosen from the series consisting of hydrogen, halogen (C_1-C_4)-alkyl, (C_1-C_4)-alkyl-O- and NC-;

R^{20} is hydrogen;

R^{21} is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_4)$-alkyl, HO-$(C_1$-$C_4)$-alkyl-, $(C_1$-$C_4)$-alkyl-O-, $(C_1$-$C_4)$-alkyl-S$(O)_m$-, H_2N-, $(C_1$-$C_4)$-alkyl-NH-, di$((C_1$-$C_4)$-alkyl)N-, $(C_1$-$C_4)$-alkyl-C(O)- and NC-;

R^{22} is a group of the formula II;

R^{24}-R^{23}- II

R^{23} is a direct bond or a chain consisting of 2, 3 or 4 chain members of which 0 or 1 chain members are hetero chain members chosen from the series consisting of N(R^{25}), O, S, S(O) and $S(O)_2$, and the other chain members are identical or different groups C(R^{26})(R^{26}), wherein two adjacent groups C(R^{26})(R^{26}) can be connected to each other by a double bond or a triple bond;

R^{24} is a 3-membered to 7-membered monocyclic ring or a 7-membered to 10-membered bicyclic ring, which rings are saturated or unsaturated and contains 0, 1 or 2 identical or different hetero ring members chosen from the series consisting of N, N(R^{32}), O, S, S(O) and $S(O)_2$, which ring is optionally substituted on ring carbon atoms by one or more identical or different substituents chosen from the series consisting of halogen, R^{33}, HO-, R^{33}-O-, R^{33}-S$(O)_m$-, H_2N-, R^{33}-NH-, R^{33}-N(R^{33})-, R^{33}-C(O)-NH-, R^{33}-C(O)-N(R^{71})-, R^{33}-$S(O)_2$-NH-, R^{33}-$S(O)_2$-N(R^{71})-, HO-C(O)-, R^{33}-O-C(O)-, H_2N-C(O)-, R^{33}-NH-C(O)-, R^{33}-N(R^{33})-C(O)-, NC-, oxo, phenyl and Het; and

R^{32} is chosen from the series consisting of hydrogen, R^{35}, R^{35}-C(O)-, R^{35}-O-C(O)- and phenyl.

7. The use according to claim 1, wherein for the compound of formula I or physiologically acceptable salt or physiologically acceptable solvate thereof:

ring A is a benzene ring which is optionally substituted by one or two identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkyl-O-;

Y is C(R^{12})=C(R^{13});

Z is $C(R^{16})$;

R^3, R^4, R^5 and R^6 are hydrogen;

R^{12}, R^{13} and R^{16} are independently of each other chosen from the series consisting of hydrogen, $(C_1\text{-}C_4)$-alkyl, $(C_1\text{-}C_4)$-alkyl-O- and NC-;

R^{20} is hydrogen;

R^{21} is chosen from the series consisting of hydrogen, halogen, $(C_1\text{-}C_4)$-alkyl, HO-$(C_1\text{-}C_4)$-alkyl-, $(C_1\text{-}C_4)$-alkyl-O-, $(C_1\text{-}C_4)$-alkyl-$S(O)_m$-, $(C_1\text{-}C_4)$-alkyl-C(O)- and NC-;

R^{22} is a group of the formula II;

$R^{24}\text{-}R^{23}\text{-}$ II

R^{23} is a direct bond or a chain consisting of 2, 3 or 4 chain members of which 0 or 1 chain members are hetero chain members chosen from the series consisting of $N(R^{25})$, O, S, S(O) and $S(O)_2$, and the other chain members are identical or different groups $C(R^{26})(R^{26})$;

R^{24} is a benzene ring which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, R^{33}, HO-, R^{33}-O-, R^{33}-$S(O)_m$-, H_2N-, R^{33}-NH-, R^{33}-$N(R^{33})$-, R^{33}-C(O)-NH-, R^{33}-$S(O)_2$-NH-, HO-C(O)-, R^{33}-O-C(O)-, H_2N-C(O)-, R^{33}-NH-C(O)-, R^{33}-$N(R^{33})$-C(O)- and NC-;

provided that the total number of C, N, O and S atoms which is present in the two groups R^{23} and R^{24}, is at least 5;

R^{25} is chosen from the series consisting of hydrogen and $(C_1\text{-}C_4)$-alkyl;

R^{26}, independently of each other group R^{26}, is chosen from the series consisting of hydrogen, fluorine, $(C_1\text{-}C_4)$-alkyl and HO-, or two of the groups R^{26} which are bonded to the same carbon atom in the chain, together with the carbon atom carrying them, form a cyclopropane ring;

R^{33} is, independently of each other group R^{33}, chosen from the series consisting of (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl and (C_3-C_7)-cycloalkyl-(C_1-C_2)-alkyl-, which are all optionally substituted by one or more identical or different substituents R^{70};

R^{50} is chosen from the series consisting of -OH, -NH_2 and OCH_3;
R^{70} is chosen from the series consisting of HO- and R^{71}-O-;

R^{71} is (C_1-C_4)-alkyl;

m, independently of each other number m, is an integer chosen from the series consisting of 0 and 2;

cycloalkyl, independently of each other group cycloalkyl, and independently of any other substituents on cycloalkyl, is optionally substituted by one or more identical or different substituents chosen from fluorine and (C_1-C_4)-alkyl; and

alkyl, independently of each other group alkyl, and independently of any other substituents on alkyl, is optionally substituted by one or more fluorine substituents.

8. The use according to claim 1, wherein the compound is 2-[4-methylsulfanyl-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

9. The use according to claim 1, wherein the compound is 2-[4-ethoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

10. The use according to claim 1, wherein the compound is 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

11. The use according to claim 1, wherein the compound is 2-[4-methoxy-3-(1-m-tolyl-cyclopropylmethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

12. The use according to claim 1, wherein the compound is 2-[3-(2-m-tolyl-ethoxy)-4-trifluoromethyl-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

13. The use according to claim 1, wherein the compound is 2-(3-{2-[3-(2-hydroxy-ethyl)-phenyl]-ethoxy}-4-methoxy-benzoylamino)-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

14. The use according to claim 1, wherein the compound is 2-{[6-methoxy-5-(2-m-tolyl-ethoxy)-pyridine-3-carbonyl]-amino}-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

15. The use according to claim 1, wherein the compound is 2-[(6-methoxy-3′-trifluoromethoxy-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

16. The use according to claim 1, wherein the compound is 2-[(3′-chloro-6-methoxy-2′-methyl-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

17. The use according to claim 1, wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis, cardiac fibrosis, vascular fibrosis, renal fibrosis, liver fibrosis, and fibrosing skin conditions.

18. The use according to claim 1, wherein the fibrotic disease is selected from the group consisting of idiopathic lung fibrosis, renal tubulointerstitial fibrosis, perivascular fibrosis, keloid formation, collagenosis, scleroderma, progressive systemic sclerosis, nephrogenic fibrosing dermopathy, and Dupuytren's contracture.

19. The use according to claim 1, wherein the fibrotic disease is progressive systemic sclerosis.

20. The use according to claim 19, wherein the compound is 2-[4-methylsulfanyl-3-(2-m-tolyl-ethoxy)-benzoylamino-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

21. The use according to claim 19, wherein the compound is 2-[4-ethoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

22. The use according to claim 19, wherein the compound is 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

23. The use according to claim 19, wherein the compound is 2-[4-methoxy-3-(1-m-tolyl-cyclopropylmethoxy)-benzoylam ino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

24. The use according to claim 19, wherein the compound is 2-[3-(2-m-tolyl-ethoxy)-4-trifluoromethyl-benzoylam ino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

25. The use according to claim 19, wherein the compound is 2-(3-{2-(3-(2-hydroxy-ethyl)-phenylFethoxy}-4-methoxy-benzoylamino)-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

26. The use according to claim 19, wherein the compound is 2-{[6-methoxy-5-(2-m-tolyl-ethoxy)-pyridine-3-carbonyl]-amino}-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

27. The use according to claim 19, wherein the compound is 2-[(6-methoxy-3′-trifluoromethoxy-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

28. The use according to claim 19, wherein the compound is 2-[(3′-chloro-6-methoxy-2′-methyl-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

29. The use according to claim 1, wherein the fibrotic disease is scleroderma.

30. The use according to claim 29, wherein the compound is 244-methylsulfanyl-3-(2-m-tolyl-ethoxy)-benzoylam inoFindane-2-carboxylic acid, or a physiologically acceptable salt thereof.

31. The use according to claim 29, wherein the compound is 2-[4-ethoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

32. The use according to claim 29, wherein the compound is 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

33. The use according to claim 29, wherein the compound is 2-[4-methoxy-3-(1-m-tolyl-cyclopropylmethoxy)-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

34. The use according to claim 29, wherein the compound is 2-[3-(2-m-tolyl-ethoxy)-4-trifluoromethyl-benzoylamino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

35. The use according to claim 29, wherein the compound is 2-(3-{2(3-[3(2-hydroxy-ethyl)-pheny]ethoxy}-4-methoxy-benzoylamino)-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

36. The use according to claim 29, wherein the compound is 2-{[6-methoxy-5-(2-m-tolyl-ethoxy)-pyridine-3-carbonyl]-am inol-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

37. The use according to claim 29, wherein the compound is 2-[(6-methoxy-3′-trifluoromethoxy-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.

38. The use according to claim 29, wherein the compound is 2-[(3′-chloro-6-methoxy-2′-methyl-biphenyl-3-carbonyl)-amino]-indane-2-carboxylic acid, or a physiologically acceptable salt thereof.